Solubilized Estradiol Soft Capsules for Vaginal Atrophy Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for vulvovaginal atrophy (VVA) in postmenopausal women, such as oral estrogen administration, face compliance issues and do not effectively address vaginal atrophy symptoms, including increased vaginal pH and susceptibility to infections.
Innovation Solution
A soft gel vaginal pharmaceutical composition containing solubilized estradiol and a medium chain oil solubilizing agent, designed to improve ease of administration, safety, and efficacy, with a pessary formulation that includes a therapeutically effective amount of estradiol and a solubilizing agent like caprylic/capric triglyceride.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral estrogen administration is used to treat vulvovaginal atrophy, then systemic estrogenization is achieved, but compliance issues occur and vaginal atrophy symptoms are not effectively addressed
Solution Approach 1:
The patent transitions from systemic oral estrogen administration to local vaginal delivery of estradiol. The vaginal tablet formulation provides localized treatment directly at the site of atrophy (vulvovaginal tissue), improving effectiveness while reducing compliance issues associated with oral medications. The local delivery mechanism ensures the drug acts where it is needed most without requiring systemic absorption.
2Reliability
If existing vaginal estrogen formulations are used, then vaginal atrophy symptoms are addressed, but compliance issues persist due to administration problems
Solution Approach 1:
The patent modifies the physical and chemical parameters of the estradiol formulation by creating a soluble estradiol capsule. The capsule contains estradiol dissolved in a specific solvent system with controlled release properties, changing the delivery parameters to improve ease of administration while maintaining therapeutic effectiveness. The soluble formulation allows for better dissolution and absorption characteristics.
3Reliability
If conventional estradiol formulations are used, then treatment is provided, but vaginal discharge increases and safety issues occur
Solution Approach 1:
The patent extracts and removes the harmful component (excessive vaginal discharge) from the treatment outcome by optimizing the formulation. The soluble estradiol capsule formulation is designed to minimize discharge while maintaining therapeutic effect. The extraction of harmful effects is achieved through careful selection of solubilizing agents and controlled release mechanisms that prevent excessive secretion.
4Reliability
If estradiol is administered to treat VVA, then therapeutic concentration is achieved, but vaginal pH increases creating infection susceptibility
Solution Approach 1:
The patent changes the chemical parameters of the formulation by using specific solubilizing agents that maintain optimal vaginal pH. The soluble estradiol capsule contains a buffered system or pH-modifying excipients that prevent excessive pH elevation while ensuring adequate estradiol absorption. This parameter control maintains the vaginal environment's natural protective acidity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides improved patient compliance, minimizes vaginal discharge, and achieves a therapeutically effective estradiol concentration in the vagina, reducing symptoms like vaginal dryness and pH, and increasing superficial vaginal cells while minimizing infections.
Implementation Method 1
a solubilizing agent comprising a medium chain oil
Data Source
AI summary
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.